2025年第一季度全球IPO报告(英)

Guide to going publicStrategic considerations before, during and after IPOGoing public03Alternative financing strategiesWhen can you go public?06How can you structure your IPO?1012The EY team - with you all the way2 | Guide to going publicCritical success factors09Where can you list your company?08Why are you going public?What is an initial public offering (IPO)?The EY IPO value journeyIPO readiness assessmentContacts1314161807Motivations for going public05Pros and cons of going publicWho are the key players?1104Companiesthat are fullypreparedwillbe able to createvalue and fully leverage the IPO windowsof opportunity.Companies that have completed a successful IPO know the process involves the complete transformation of the people, processes and culture of the organization from a private enterprise to a public one. Preparation is critical. Successful IPO candidates often spend twoyears or more building business processes and infrastructure,recruiting executive and advisory talent, getting in front of financialand reporting issues, and mastering the essential board of directors’commitments to go public. During the journey to become a publiccompany, an organization must prepare not only for the definingmoment of the IPO ceremony — the ringing of the bell — but also for awhole new phase of corporate life after the IPO takes place. That's why those that outperform the market treat the IPO as a long-term transformational process, an IPO journey.The EY team is a key member of your external IPO team. EY teamshave worked with business owners and management teams offamily businesses, scaled up and high-growth companies as well asprivate equity- (PE-) or venture capital- (VC-) backed companiesconsidering their strategic options for funding for growth, includinga public listing. EY teams are made up of professionals with extensive, proven experience with domestic and internationalcapital markets. EY professionals have deep knowledge of yourindustry, which allows us to create multidisciplinary teams that willsteer you onward, through and beyond your IPO, and support yourplans for growth.This Guide to going public will give you an initial overview andchecklists of the key phases in going public from a globalperspective.It is based on EY insights from many IPO transactions, to help you begin your IPO value journey, so that you are well prepared to transform your private company into a successful public company thatcontinually delivers value to its shareholders. With extensive experience helping companies prepare, grow and adapt to life as apublic entity, EY teams are well positioned to take you on your IPOjourney, providing tailored support and integrated services before,during and after your IPO.EY IPO leaders in your region and the EY global network will serve you from evaluating strategic options pre-IPO to setting you on the right path to support growth post-IPO, while anticipating the expectations of different stakeholders — from regulators, board of direc

立即下载
综合
2025-09-08
20页
2.31M
收藏
分享

2025年第一季度全球IPO报告(英),点击即可下载。报告格式为PDF,大小2.31M,页数20页,欢迎下载。

本报告共20页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共20页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
表6: 上周重要上市公司公告
综合
2025-09-08
来源:医药生物行业周报:创新药行情开始分化,高端器械及AI医疗有望接力
查看原文
表4: 近期行业重要政策梳理
综合
2025-09-08
来源:医药生物行业周报:创新药行情开始分化,高端器械及AI医疗有望接力
查看原文
表3: 医药生物关注个股-涨跌幅及估值
综合
2025-09-08
来源:医药生物行业周报:创新药行情开始分化,高端器械及AI医疗有望接力
查看原文
图17: 医药板块个股上周表现(港股)
综合
2025-09-08
来源:医药生物行业周报:创新药行情开始分化,高端器械及AI医疗有望接力
查看原文
图16: 医药板块个股上周表现(A 股)
综合
2025-09-08
来源:医药生物行业周报:创新药行情开始分化,高端器械及AI医疗有望接力
查看原文
图14: 细分子行业周涨跌幅 图15: 细分子行业月涨跌幅
综合
2025-09-08
来源:医药生物行业周报:创新药行情开始分化,高端器械及AI医疗有望接力
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起